Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study

B Vellas; L Hausner; L Frolich; C Cantet; V Gardette; E Reynish; S Gillette; E Aguera-Morales; S Auriacombe; M Boada; R Bullock; J Byrne; V Camus; A Cherubini; M Eriksdotter-Jonhagen; G B Frisoni; S Hasselbalch; R Jones; P Martinez-Lage; M O Rikkert; M Tsolaki; P-J Ousset; F Pasquier; J M Ribera-Casado; A S Rigaud; P Robert; G Rodriguez; E Salmon; A Salva; P Scheltens; AL Schneider; A Sinclair; L Spiru; J Touchon; D Zekry; B Winblad; S Andrieu

Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study

B Vellas, L Hausner, L Frolich, C Cantet, V Gardette, E Reynish, S Gillette, E Aguera-Morales, S Auriacombe, M Boada, R Bullock, J Byrne, V Camus, A Cherubini, M Eriksdotter-Jonhagen, G B Frisoni, S Hasselbalch, R Jones, P Martinez-Lage, M O RikkertM Tsolaki, P-J Ousset, F Pasquier, J M Ribera-Casado, A S Rigaud, P Robert, G Rodriguez, E Salmon, A Salva, P Scheltens, AL Schneider, A Sinclair, L Spiru, J Touchon, D Zekry, B Winblad, S Andrieu

Department of Clinical Medicine

40 Citations (Scopus)

Abstract

The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North, South, West) and investigated with biannual follow-up over 2 years. Primary outcomes were cognitive, functional and behavioral measures. Caregiver burden, hospital admission and admission to nursing home were also recorded. Participant cognitive function declined non-linearly over time (MMSE: -1.5 pts/first year, -2.5 pts/second year; ADAScog: + 3.5 pts/first year, + 4.8 pts/second year), while the progression of behavioral disturbances (NPI scale) was linear. Neither scale showed regional differences, and progression of the disease was similar across Europe despite different health care systems. Functional decline (ADL, IADL) tended to progress more rapidly in Southern Europe (p=0.09), while progression of caregiver burden (Zarit Burden Interview) was most rapid in Northern Europe (5.6 pts/y, p=0.04). Incidences of hospital admission (10.44, 95%CI: 8.13-12.75, p<0.001) and admission to nursing home (2.97, 95%CI: 1.83-4.11, p<0.001) were lowest in Southern Europe. In general cognitive and functional decline was slower than in former cohorts. European geographical location reflecting differences in culture and in health care system does not impact on the progression of AD but does influence the management of AD subjects and caregiver burden.

Original language	English
Journal	Current Alzheimer Research
Volume	9
Issue number	8
Pages (from-to)	902-12
Number of pages	11
ISSN	1567-2050
Publication status	Published - 2012

Access to Document

http://www.ingentaconnect.com/content/ben/car/2012/00000009/00000008/art00003?token=004813d381867232d45232b6d24417b425774414723703568293c62207d673f582f6b437

Cite this

Vellas, B., Hausner, L., Frolich, L., Cantet, C., Gardette, V., Reynish, E., Gillette, S., Aguera-Morales, E., Auriacombe, S., Boada, M., Bullock, R., Byrne, J., Camus, V., Cherubini, A., Eriksdotter-Jonhagen, M., Frisoni, G. B., Hasselbalch, S., Jones, R., Martinez-Lage, P., ... Andrieu, S. (2012). Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study. Current Alzheimer Research, 9(8), 902-12. http://www.ingentaconnect.com/content/ben/car/2012/00000009/00000008/art00003?token=004813d381867232d45232b6d24417b425774414723703568293c62207d673f582f6b437

Vellas, B, Hausner, L, Frolich, L, Cantet, C, Gardette, V, Reynish, E, Gillette, S, Aguera-Morales, E, Auriacombe, S, Boada, M, Bullock, R, Byrne, J, Camus, V, Cherubini, A, Eriksdotter-Jonhagen, M, Frisoni, GB, Hasselbalch, S, Jones, R, Martinez-Lage, P, Rikkert, MO, Tsolaki, M, Ousset, P-J, Pasquier, F, Ribera-Casado, JM, Rigaud, AS, Robert, P, Rodriguez, G, Salmon, E, Salva, A, Scheltens, P, Schneider, AL, Sinclair, A, Spiru, L, Touchon, J, Zekry, D, Winblad, B & Andrieu, S 2012, 'Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study', Current Alzheimer Research, vol. 9, no. 8, pp. 902-12. <http://www.ingentaconnect.com/content/ben/car/2012/00000009/00000008/art00003?token=004813d381867232d45232b6d24417b425774414723703568293c62207d673f582f6b437>

@article{0d41ce69ff994b5f8dbb20d7cac5b6f5,

title = "Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study",

abstract = "The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North, South, West) and investigated with biannual follow-up over 2 years. Primary outcomes were cognitive, functional and behavioral measures. Caregiver burden, hospital admission and admission to nursing home were also recorded. Participant cognitive function declined non-linearly over time (MMSE: -1.5 pts/first year, -2.5 pts/second year; ADAScog: + 3.5 pts/first year, + 4.8 pts/second year), while the progression of behavioral disturbances (NPI scale) was linear. Neither scale showed regional differences, and progression of the disease was similar across Europe despite different health care systems. Functional decline (ADL, IADL) tended to progress more rapidly in Southern Europe (p=0.09), while progression of caregiver burden (Zarit Burden Interview) was most rapid in Northern Europe (5.6 pts/y, p=0.04). Incidences of hospital admission (10.44, 95%CI: 8.13-12.75, p<0.001) and admission to nursing home (2.97, 95%CI: 1.83-4.11, p<0.001) were lowest in Southern Europe. In general cognitive and functional decline was slower than in former cohorts. European geographical location reflecting differences in culture and in health care system does not impact on the progression of AD but does influence the management of AD subjects and caregiver burden.",

author = "B Vellas and L Hausner and L Frolich and C Cantet and V Gardette and E Reynish and S Gillette and E Aguera-Morales and S Auriacombe and M Boada and R Bullock and J Byrne and V Camus and A Cherubini and M Eriksdotter-Jonhagen and Frisoni, {G B} and S Hasselbalch and R Jones and P Martinez-Lage and Rikkert, {M O} and M Tsolaki and P-J Ousset and F Pasquier and Ribera-Casado, {J M} and Rigaud, {A S} and P Robert and G Rodriguez and E Salmon and A Salva and P Scheltens and AL Schneider and A Sinclair and L Spiru and J Touchon and D Zekry and B Winblad and S Andrieu",

year = "2012",

language = "English",

volume = "9",

pages = "902--12",

journal = "Current Alzheimer Research",

issn = "1567-2050",

publisher = "Bentham Science Publishers",

number = "8",

}

TY - JOUR

T1 - Progression of Alzheimer Disease in Europe

T2 - Data from the European ICTUS Study

AU - Vellas, B

AU - Hausner, L

AU - Frolich, L

AU - Cantet, C

AU - Gardette, V

AU - Reynish, E

AU - Gillette, S

AU - Aguera-Morales, E

AU - Auriacombe, S

AU - Boada, M

AU - Bullock, R

AU - Byrne, J

AU - Camus, V

AU - Cherubini, A

AU - Eriksdotter-Jonhagen, M

AU - Frisoni, G B

AU - Hasselbalch, S

AU - Jones, R

AU - Martinez-Lage, P

AU - Rikkert, M O

AU - Tsolaki, M

AU - Ousset, P-J

AU - Pasquier, F

AU - Ribera-Casado, J M

AU - Rigaud, A S

AU - Robert, P

AU - Rodriguez, G

AU - Salmon, E

AU - Salva, A

AU - Scheltens, P

AU - Schneider, AL

AU - Sinclair, A

AU - Spiru, L

AU - Touchon, J

AU - Zekry, D

AU - Winblad, B

AU - Andrieu, S

PY - 2012

Y1 - 2012

N2 - The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North, South, West) and investigated with biannual follow-up over 2 years. Primary outcomes were cognitive, functional and behavioral measures. Caregiver burden, hospital admission and admission to nursing home were also recorded. Participant cognitive function declined non-linearly over time (MMSE: -1.5 pts/first year, -2.5 pts/second year; ADAScog: + 3.5 pts/first year, + 4.8 pts/second year), while the progression of behavioral disturbances (NPI scale) was linear. Neither scale showed regional differences, and progression of the disease was similar across Europe despite different health care systems. Functional decline (ADL, IADL) tended to progress more rapidly in Southern Europe (p=0.09), while progression of caregiver burden (Zarit Burden Interview) was most rapid in Northern Europe (5.6 pts/y, p=0.04). Incidences of hospital admission (10.44, 95%CI: 8.13-12.75, p<0.001) and admission to nursing home (2.97, 95%CI: 1.83-4.11, p<0.001) were lowest in Southern Europe. In general cognitive and functional decline was slower than in former cohorts. European geographical location reflecting differences in culture and in health care system does not impact on the progression of AD but does influence the management of AD subjects and caregiver burden.

AB - The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North, South, West) and investigated with biannual follow-up over 2 years. Primary outcomes were cognitive, functional and behavioral measures. Caregiver burden, hospital admission and admission to nursing home were also recorded. Participant cognitive function declined non-linearly over time (MMSE: -1.5 pts/first year, -2.5 pts/second year; ADAScog: + 3.5 pts/first year, + 4.8 pts/second year), while the progression of behavioral disturbances (NPI scale) was linear. Neither scale showed regional differences, and progression of the disease was similar across Europe despite different health care systems. Functional decline (ADL, IADL) tended to progress more rapidly in Southern Europe (p=0.09), while progression of caregiver burden (Zarit Burden Interview) was most rapid in Northern Europe (5.6 pts/y, p=0.04). Incidences of hospital admission (10.44, 95%CI: 8.13-12.75, p<0.001) and admission to nursing home (2.97, 95%CI: 1.83-4.11, p<0.001) were lowest in Southern Europe. In general cognitive and functional decline was slower than in former cohorts. European geographical location reflecting differences in culture and in health care system does not impact on the progression of AD but does influence the management of AD subjects and caregiver burden.

M3 - Journal article

SN - 1567-2050

VL - 9

SP - 902

EP - 912

JO - Current Alzheimer Research

JF - Current Alzheimer Research

IS - 8

ER -

Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study

Abstract

Access to Document

Fingerprint

Cite this